A randomized, double-blind, phase III multi-center study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using BF-RhodoLED lamp

Trial Profile

A randomized, double-blind, phase III multi-center study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using BF-RhodoLED lamp

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Actinic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Biofrontera Bioscience GmbH
  • Most Recent Events

    • 11 May 2016 According to Biofrontera media release, the the U.S. Food and Drug Administration (FDA) has granted approval of its combination topical prescription drug Ameluz (BF-200 ALA) and medical device BF-RhodoLED for photodynamic therapy (PDT) treatment of mild to moderate actinic keratosis (AK) on the face and scalp.
    • 04 Apr 2016 According to Biofrontera media release, company has announced an update on the latest progress of its New Drug Application (NDA). The FDA has issued the proposed labeling for BF-200 ALA, the Company's prescription drug for the treatment of mild to moderate actinic keratosis (AK) on the face and scalp.
    • 27 Feb 2016 Results published in the British Journal of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top